Posted by Michael Wonder on 05 Feb 2024
Selinexor in combination with bortezomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma
2 February 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the use of selinexor in combination with bortezomib and dexamethasone in the NHS in England.
Selinexor, when used in combination with bortezomib and dexamethasone, is recommended as an option for the treatment of adults with multiple myeloma only if they have only had one previous line of treatment, their condition is refractory to both daratumumab and lenalidomide and Menarini provides selinexor according to the commercial arrangement.
